Core Viewpoint - Karolinska Development's portfolio company Dilafor has received a US patent for its drug candidate tafoxiparin, which is aimed at priming labor, marking a significant step as it progresses into Phase 3 clinical trials [1][2][3]. Group 1: Patent and Development - The US Patent and Trademark Office has granted a patent for tafoxiparin, providing intellectual property protection until at least May 2043 [2]. - Tafoxiparin is designed to prepare the cervix and uterus for labor, potentially increasing the likelihood of normal vaginal deliveries and reducing the need for traditional hospital-based induction treatments [3]. - The drug is positioned to meet new national guidelines recommending labor induction at 39 weeks in the US and 40-41 weeks in Europe, which may lead to an increase in births requiring medical intervention [3]. Group 2: Company Insights - Karolinska Development holds a 3% direct ownership and a 29% indirect ownership interest in Dilafor [5]. - The CEO of Karolinska Development, Viktor Drvota, emphasized the importance of strengthening intellectual property as Dilafor advances in clinical development, highlighting the potential for a safe at-home treatment option for pregnant women [4]. - The company focuses on identifying and investing in breakthrough medical innovations in the Nordic region, aiming to create and grow companies that can deliver impactful medical products [6][8].

Group 1 - Karolinska Development's portfolio company AnaCardio has completed enrollment in the phase 2a part of its clinical study GOAL-HF1, which evaluates the drug candidate AC01 in patients with heart failure and reduced ejection fraction, with results expected by the end of the year [1][4] - The phase 2a study includes 26 patients and aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics after 28 days of treatment, conducted at 13 specialized heart failure centers across Sweden, the Netherlands, Italy, and the UK [3] - Karolinska Development holds a 10 percent ownership stake in AnaCardio, indicating a vested interest in the success of the clinical study and the advancement of the drug candidate [4] Group 2 - AnaCardio AB is a privately held Swedish biopharmaceutical company focused on developing novel drugs for heart failure, with its lead asset AC01 currently in a clinical phase 1b/2a study [2] - Karolinska Development is a Nordic life sciences investment company that identifies and invests in breakthrough medical innovations, aiming to create and grow companies that develop these innovations into commercial products [5][6] - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by a team of experienced investment professionals and a strong global network [7]

Core Viewpoint - Umecrine Cognition's drug candidate golexanolone shows promise in reversing neuroinflammation in a Parkinson's disease model, indicating its potential as a chronic treatment option [1][3]. Company Overview - Karolinska Development AB holds a 73% ownership stake in Umecrine Cognition prior to dilution, emphasizing its significant investment in innovative medical solutions [4]. - The company focuses on identifying and developing breakthrough medical innovations in the Nordic region, aiming to create and grow companies that advance these innovations into commercial products [5][6]. Research Findings - A preclinical study demonstrated that golexanolone completely reverses the activation of immune cells responsible for neuroinflammation in the brain, which is crucial for controlling voluntary movement and posture [3]. - The treatment with golexanolone not only reversed the increase of inflammation-promoting proteins but also provided robust protection against neuroinflammation as early as three weeks after disease onset [3]. - After nine weeks, golexanolone continued to counteract inflammation and aided in restoring protective immune cells, indicating a sustained effect on harmful brain inflammation [3]. Academic Collaboration - The study was conducted in collaboration with academic partners at Centro de Investigación Príncipe Felipe in Valencia, Spain, highlighting the importance of academic partnerships in advancing medical research [4].

Core Viewpoint - Karolinska Development AB emphasizes its clear strategy and stable scientific foundation for its investment portfolio, focusing on patient benefits amidst challenging market conditions [1]. Significant Events - Organon plans to discontinue the clinical development of drug candidate OG-6219, following Phase 2 study results [3]. - Umecrine Cognition presented preclinical data on golexanolone's effects on Parkinsonian symptoms at the AD/PD 2025 conference [4]. - Umecrine Cognition received a USD 420,000 research grant from The Michael J. Fox Foundation for golexanolone studies [4]. - OssDsign achieved a milestone of treating 10,000 patients with its bone graft product in the US market [4]. - Karolinska Development divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million [4]. Financial Update - The net profit/loss for Q2 2025 was SEK -73.3 million, compared to SEK -16.0 million in Q2 2024 [5]. - The total fair value of the portfolio decreased to SEK 1,384.9 million at the end of June 2025, down from SEK 1,434.2 million [5]. - Net asset value at the end of June 2025 was SEK 1,148.6 million, or SEK 4.3 per share, compared to SEK 1,238.2 million, or SEK 4.6 per share, at the end of June 2024 [5]. - Cash and cash equivalents increased by SEK 20.0 million, totaling SEK 71.1 million on June 30, 2025 [5].

Core Insights - Modus Therapeutics has successfully raised SEK 28.3 million through a unit issue with a subscription rate of 189 percent, indicating strong investor confidence [1][2][4] - The net proceeds amount to SEK 24.4 million, primarily allocated for clinical activities, including a phase 2 study of the drug candidate sevuparin for chronic kidney disease [3] - Karolinska Development holds a 66 percent direct and 8 percent indirect ownership in Modus Therapeutics, reflecting its significant stake in the company [5] Financial Details - The rights issue raised SEK 28.3 million, with a subscription rate of 189 percent, eliminating the need for guarantee commitments [1][2] - Approximately SEK 5 million of the net proceeds will be used to offset loans from Karolinska Development, while the majority will support ongoing clinical activities [3] - The financing is expected to sustain operations until the end of 2026, including potential proceeds from the exercise of warrants [3] Company Background - Karolinska Development AB is a Nordic life sciences investment company focused on breakthrough medical innovations and the growth of companies that advance these innovations into commercial products [6][8] - The company has access to world-class medical innovations from leading universities and research institutes in the Nordic region, aiming to build companies around top scientists [7] - Karolinska Development's portfolio includes eleven companies targeting innovative treatments for serious diseases, supported by an experienced management team [8]

Core Viewpoint - Umecrine Cognition has successfully raised SEK 24.6 million through a convertible loan to support its ongoing clinical Phase 1b/2a study of golexanolone in primary biliary cholangitis, with participation from existing shareholders including Karolinska Development [1][3]. Group 1: Clinical Study Details - Umecrine Cognition is conducting the second part of its clinical Phase 1b/2a study, aiming to recruit 84 patients across over 30 sites in eight countries [2]. - The first part of the study concluded with interim results indicating that golexanolone was well-tolerated, safe, and resulted in only mild adverse events, achieving clinically relevant drug exposure levels and positive outcomes in anxiety and depression scoring [2]. Group 2: Funding and Ownership - The convertible loan, which includes attached share options, is directed to a consortium of investors, including Karolinska Development, AB Ility, and Ribbskottet AB, and will finance the clinical trial and operational expenses [3]. - Karolinska Development currently holds a 73% ownership stake in Umecrine Cognition, which will decrease to 62% upon conversion of the loan and full exercise of the share options [4]. Group 3: Company Background - Karolinska Development is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the region [5][6]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases and is supported by a team of experienced investment professionals [7].

Core Insights - Modus Therapeutics has successfully completed patient enrollment for part 1 of its clinical phase 2a study evaluating sevuparin as a treatment for chronic kidney disease with anemia [1][2] - The study aims to assess the safety and dosing levels of sevuparin in patients with chronic kidney disease (stage 3-5) and healthy volunteers, conducted in Italy [2] - Karolinska Development holds a 66% ownership stake in Modus Therapeutics, indicating significant investment in the company's potential [3] Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [4][5] - The company aims to build companies around leading scientists and experienced management teams, co-funded by international investors to enhance the likelihood of success [5][6] - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by a strong global network [6]

Core Insights - Organon has decided to discontinue the clinical development of the drug candidate OG-6219 following the results of a Phase 2 clinical study that did not show improvement in endometriosis-related pain compared to placebo [1][2]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [5][6]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases and is led by a team of investment professionals with a strong track record [7]. Financial Implications - Prior to the announcement, Karolinska Development estimated the risk-adjusted net present value (rNPV) of future cash flows from earn-out payments at SEK 76.2 million. The company recognizes the need for an impairment if Organon discontinues the project, with final impairment details to be presented in the interim report for Q2 2025 [4].

Core Viewpoint - Karolinska Development AB has divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million, which strengthens the company's liquidity and allows for prioritization of other investments with greater value creation potential [1][2]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region, investing in the creation and growth of companies that advance these innovations into commercial products [4][5]. - The company has access to world-class medical innovations from the Karolinska Institutet and other leading universities and research institutes in the Nordic region, aiming to build companies around leading scientists supported by experienced management teams [5][6]. Investment Strategy - The divestment from OssDsign reflects a strategic decision to realize profits and enhance the financial position of Karolinska Development, enabling the company to invest in other holdings with higher potential returns [2][3]. - Following the divestment, Karolinska Development has no direct ownership in OssDsign but retains indirect ownership through the KCIF Co-Investment Fund [3]. Portfolio and Management - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for life-threatening or serious debilitating diseases, led by an entrepreneurial team of investment professionals with a proven track record [6].

Core Viewpoint - Modus Therapeutics is conducting a fully secured rights issue to raise SEK 28.3 million for the continued development of its drug candidate sevuparin, aimed at treating chronic kidney disease with anemia [1][2][3]. Group 1: Rights Issue Details - The rights issue will provide SEK 28.3 million before issue costs, subject to approval at an extraordinary general meeting on July 29, 2025 [2][3]. - Major shareholders, including Karolinska Development, have committed SEK 17.7 million, covering 62.7% of the rights issue, with the remaining 37.3% underwritten by external parties [4]. Group 2: Purpose and Impact - The funds from the rights issue will be used to complete the ongoing clinical phase II study of sevuparin and to finance operations through the end of 2026 [3]. - The successful securing of the rights issue is viewed as a strong indicator of Modus Therapeutics' clinical strategy and financial health [5]. Group 3: Company Background - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [6][7]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [8].